APLS
$18.27
Revenue | $166.8Mn |
Net Profits | $-92.23Mn |
Net Profit Margins | -55.29% |
Apellis Pharmaceuticals Inc’s revenue fell -3.21% since last year same period to $166.8Mn in the Q1 2025. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -21.52% fall in its revenue since last 3-months.
Apellis Pharmaceuticals Inc’s net profit fell -38.84% since last year same period to $-92.23Mn in the Q1 2025. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -153.69% fall in its net profits since last 3-months.
Apellis Pharmaceuticals Inc’s net profit margin fell -43.45% since last year same period to -55.29% in the Q1 2025. On a quarterly growth basis, Apellis Pharmaceuticals Inc has generated -223.25% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -0.48 |
EPS Estimate Current Year | -0.48 |
Apellis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.48 - a 12.02% jump from last quarter’s estimates.
Apellis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.48.
Earning Per Share (EPS) | 0 |
Apellis Pharmaceuticals Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q2 2025. This indicates that the Apellis Pharmaceuticals Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2025-08-11 | -0.48 | 0 | 100% |
2025-05-07 | -0.54 | -0.74 | -37.04% |